J Korean Ophthalmol Soc > Volume 58(3); 2017 > Article
Journal of the Korean Ophthalmological Society 2017;58(3):296-304.
DOI: https://doi.org/10.3341/jkos.2017.58.3.296    Published online March 15, 2017.
Comparison of Choroidal Thickness Change between Ranibizumab and Aflibercept in Age-related Macular Degeneration: Six Month Results.
Im Gyu Kim, Yong Il Kim, Jin Seon Kim, Jung Ho Lee, Kyoo Won Lee, Hyun Gu Kang
Cheil Eye Hospital, Daegu, Korea. flowerchild03@hanmail.net
나이관련황반변성에서 라니비주맙과 애프리버셉트 후 맥락막두께의 변화 비교: 6개월 결과
김임규⋅김용일⋅김진선⋅이정호⋅이규원⋅강현구
제일안과병원
Correspondence:  Hyun Gu Kang,
Email: flowerchild03@hanmail.net
Received: 18 August 2016   • Revised: 18 November 2016   • Accepted: 23 January 2017
Abstract
PURPOSE
To compare the changes in subfoveal choroidal thickness between intravitreal aflibercept and ranibizumab injection in wet age-related macular degeneration (AMD). METHODS: Fifty patients with wet AMD patients who were treated with aflibercpet or ranibizumab were evaluated retrospectively. All patients were treated with pro re nata after 3 consecutive monthly injections and were followed up for at least 6 months. We measured subfoveal choroidal thickness (SFCT) using enhanced depth imaging spectral-domain optical coherence tomography before the first injection and 1, 2, 3, and 6 months after initial injection. RESULTS: The SFCT measures before initial injection and 1, 2, 3, and 6 months after initial injection were 244.94 ± 103.77 µm, 219.04 ± 95.89 µm, 208.74 ± 91.03 µm, 203.64 ± 91.35 µm, and 226.98 ± 96.79 µm in the aflibercept group (25 eyes) and 222.68 ± 102.04 µm, 210.23 ± 95.91 µm, 203.66 ± 99.39 µm, 197.27 ± 100.25 µm, and 210.32 ± 111.86 µm in the ranibizumab group (28 eyes). Mean change in SFCT was greater in the aflibercept group at 1 month, 2 months, and 3 months after initial injection (p < 0.05), but there was no significant difference in the mean change in SFCT between the two groups at 6 months after initial injection (p > 0.05). CONCLUSIONS: The decrease in SFCT was greater after aflibercept injection than ranibizumab injection in 3 consecutive months. However, at 6 months after initial injection, the difference in the change in SFCT was not significant.
Key Words: Aflibercept;Polypoidal choroidal vasculopathy;Ranibizumab;Subfoveal choroidal thickness;Wet age-related macular degeneration


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next